Effects of menthol on the pharmacokinetics of triazolam and phenytoin. 2015

Motohiro Hoshino, and Nobutomo Ikarashi, and Ryuta Hirobe, and Mami Hayashi, and Hironori Hiraoka, and Kohsuke Yokobori, and Takumi Ochiai, and Yoshiki Kusunoki, and Risako Kon, and Masataka Tajima, and Wataru Ochiai, and Kiyoshi Sugiyama
Department of Clinical Pharmacokinetics, Hoshi University.

We have previously shown that menthol attenuates the anticoagulant effect of warfarin by increasing the expression levels of CYP3A and CYP2C in the liver. This study evaluated the effects of menthol on the pharmacokinetics of the CYP3A substrate triazolam and the CYP2C substrate phenytoin. Menthol was orally administered to mice for 7 d. Twenty-four hours after the administration of menthol, triazolam was orally administered, and the plasma concentration was measured. In addition, the CYP3A metabolic activity for triazolam and the CYP3A expression level in the liver were determined. The effects of menthol on the pharmacokinetics of phenytoin were assessed in the same manner. In the menthol-treated group, the area under the blood concentration-time curve (AUC) of triazolam was lower and its clearance was higher compared with the control group. The CYP3A metabolic activity and CYP3A expression level in the liver were significantly increased in the menthol-treated group compared with the control group. Similarly, the AUC of phenytoin was lower and the hepatic CYP2C expression level was higher in the menthol-treated group. Thus, menthol lowered the plasma concentrations of triazolam and phenytoin when concurrently administered. These effects may be attributed to an increased metabolic activity for these drugs due to the increased expression of CYP3A and CYP2C in the liver.

UI MeSH Term Description Entries
D008297 Male Males
D008610 Menthol A monoterpene cyclohexanol produced from mint oils. Cyclohexanol, 5-methyl-2-(1-methylethyl)-,Menthol, (1alpha,2beta,5alpha)-Isomer
D008813 Mice, Inbred ICR An inbred strain of mouse that is used as a general purpose research strain, for therapeutic drug testing, and for the genetic analysis of CARCINOGEN-induced COLON CANCER. Mice, Inbred ICRC,Mice, ICR,Mouse, ICR,Mouse, Inbred ICR,Mouse, Inbred ICRC,ICR Mice,ICR Mice, Inbred,ICR Mouse,ICR Mouse, Inbred,ICRC Mice, Inbred,ICRC Mouse, Inbred,Inbred ICR Mice,Inbred ICR Mouse,Inbred ICRC Mice,Inbred ICRC Mouse
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D010936 Plant Extracts Concentrated pharmaceutical preparations of plants obtained by removing active constituents with a suitable solvent, which is evaporated away, and adjusting the residue to a prescribed standard. Herbal Medicines,Plant Extract,Extract, Plant,Extracts, Plant,Medicines, Herbal
D003577 Cytochrome P-450 Enzyme System A superfamily of hundreds of closely related HEMEPROTEINS found throughout the phylogenetic spectrum, from animals, plants, fungi, to bacteria. They include numerous complex monooxygenases (MIXED FUNCTION OXYGENASES). In animals, these P-450 enzymes serve two major functions: (1) biosynthesis of steroids, fatty acids, and bile acids; (2) metabolism of endogenous and a wide variety of exogenous substrates, such as toxins and drugs (BIOTRANSFORMATION). They are classified, according to their sequence similarities rather than functions, into CYP gene families (>40% homology) and subfamilies (>59% homology). For example, enzymes from the CYP1, CYP2, and CYP3 gene families are responsible for most drug metabolism. Cytochrome P-450,Cytochrome P-450 Enzyme,Cytochrome P-450-Dependent Monooxygenase,P-450 Enzyme,P450 Enzyme,CYP450 Family,CYP450 Superfamily,Cytochrome P-450 Enzymes,Cytochrome P-450 Families,Cytochrome P-450 Monooxygenase,Cytochrome P-450 Oxygenase,Cytochrome P-450 Superfamily,Cytochrome P450,Cytochrome P450 Superfamily,Cytochrome p450 Families,P-450 Enzymes,P450 Enzymes,Cytochrome P 450,Cytochrome P 450 Dependent Monooxygenase,Cytochrome P 450 Enzyme,Cytochrome P 450 Enzyme System,Cytochrome P 450 Enzymes,Cytochrome P 450 Families,Cytochrome P 450 Monooxygenase,Cytochrome P 450 Oxygenase,Cytochrome P 450 Superfamily,Enzyme, Cytochrome P-450,Enzyme, P-450,Enzyme, P450,Enzymes, Cytochrome P-450,Enzymes, P-450,Enzymes, P450,Monooxygenase, Cytochrome P-450,Monooxygenase, Cytochrome P-450-Dependent,P 450 Enzyme,P 450 Enzymes,P-450 Enzyme, Cytochrome,P-450 Enzymes, Cytochrome,Superfamily, CYP450,Superfamily, Cytochrome P-450,Superfamily, Cytochrome P450
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005421 Flavoring Agents Substances added to foods and medicine to improve the taste. Flavor Additives,Flavor Enhancers,Additive, Flavor,Additives, Flavor,Agent, Flavoring,Agents, Flavoring,Enhancer, Flavor,Enhancers, Flavor,Flavor Additive,Flavor Enhancer,Flavoring Agent
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014229 Triazolam A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. Apo-Triazo,Gen-Triazolam,Halcion,Trilam,U-33,030,Apo Triazo,Gen Triazolam,U 33,030,U33,030

Related Publications

Motohiro Hoshino, and Nobutomo Ikarashi, and Ryuta Hirobe, and Mami Hayashi, and Hironori Hiraoka, and Kohsuke Yokobori, and Takumi Ochiai, and Yoshiki Kusunoki, and Risako Kon, and Masataka Tajima, and Wataru Ochiai, and Kiyoshi Sugiyama
April 2014, European journal of clinical pharmacology,
Motohiro Hoshino, and Nobutomo Ikarashi, and Ryuta Hirobe, and Mami Hayashi, and Hironori Hiraoka, and Kohsuke Yokobori, and Takumi Ochiai, and Yoshiki Kusunoki, and Risako Kon, and Masataka Tajima, and Wataru Ochiai, and Kiyoshi Sugiyama
January 2008, Pharmacological reports : PR,
Motohiro Hoshino, and Nobutomo Ikarashi, and Ryuta Hirobe, and Mami Hayashi, and Hironori Hiraoka, and Kohsuke Yokobori, and Takumi Ochiai, and Yoshiki Kusunoki, and Risako Kon, and Masataka Tajima, and Wataru Ochiai, and Kiyoshi Sugiyama
March 1981, Neurology,
Motohiro Hoshino, and Nobutomo Ikarashi, and Ryuta Hirobe, and Mami Hayashi, and Hironori Hiraoka, and Kohsuke Yokobori, and Takumi Ochiai, and Yoshiki Kusunoki, and Risako Kon, and Masataka Tajima, and Wataru Ochiai, and Kiyoshi Sugiyama
June 2012, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,
Motohiro Hoshino, and Nobutomo Ikarashi, and Ryuta Hirobe, and Mami Hayashi, and Hironori Hiraoka, and Kohsuke Yokobori, and Takumi Ochiai, and Yoshiki Kusunoki, and Risako Kon, and Masataka Tajima, and Wataru Ochiai, and Kiyoshi Sugiyama
September 1979, British journal of cancer,
Motohiro Hoshino, and Nobutomo Ikarashi, and Ryuta Hirobe, and Mami Hayashi, and Hironori Hiraoka, and Kohsuke Yokobori, and Takumi Ochiai, and Yoshiki Kusunoki, and Risako Kon, and Masataka Tajima, and Wataru Ochiai, and Kiyoshi Sugiyama
March 2006, Methods and findings in experimental and clinical pharmacology,
Motohiro Hoshino, and Nobutomo Ikarashi, and Ryuta Hirobe, and Mami Hayashi, and Hironori Hiraoka, and Kohsuke Yokobori, and Takumi Ochiai, and Yoshiki Kusunoki, and Risako Kon, and Masataka Tajima, and Wataru Ochiai, and Kiyoshi Sugiyama
June 1985, British journal of clinical pharmacology,
Motohiro Hoshino, and Nobutomo Ikarashi, and Ryuta Hirobe, and Mami Hayashi, and Hironori Hiraoka, and Kohsuke Yokobori, and Takumi Ochiai, and Yoshiki Kusunoki, and Risako Kon, and Masataka Tajima, and Wataru Ochiai, and Kiyoshi Sugiyama
September 1998, Pharmacology & toxicology,
Motohiro Hoshino, and Nobutomo Ikarashi, and Ryuta Hirobe, and Mami Hayashi, and Hironori Hiraoka, and Kohsuke Yokobori, and Takumi Ochiai, and Yoshiki Kusunoki, and Risako Kon, and Masataka Tajima, and Wataru Ochiai, and Kiyoshi Sugiyama
October 2020, Pharmaceutics,
Motohiro Hoshino, and Nobutomo Ikarashi, and Ryuta Hirobe, and Mami Hayashi, and Hironori Hiraoka, and Kohsuke Yokobori, and Takumi Ochiai, and Yoshiki Kusunoki, and Risako Kon, and Masataka Tajima, and Wataru Ochiai, and Kiyoshi Sugiyama
April 1998, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!